Literature DB >> 8150545

Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line.

K Chang1, I Pastan.   

Abstract

MAb KI recognizes a cell-surface glycoprotein (MW approximately 40 kDa) present in ovarian carcinomas, malignant mesotheliomas, squamous-cell carcinomas and normal mesothelial cells. In this study, expression screening was used to isolate cDNA clones encoding an antigen recognized by MAb KI from a cDNA library made from a human ovarian carcinoma cell line (OVCAR-3). Subsequently, other clones were isolated by DNA hybridization using a cDNA probe derived from one of the initial clones. The sequence of all the clones was similar. The longest cDNA contains 2,444 base pairs, and encodes a polypeptide of 263 amino acids with a calculated molecular weight of 30,511 daltons. The nucleotide sequence and deduced amino-acid sequence of the protein show no homology to other sequences in current data bases. In vitro translation of RNA transcripts from the cDNA inserts yielded polypeptides of 29 and 30 kDa. Similar-sized proteins were obtained upon expression of the cDNA in Escherichia coli, and these proteins were reactive with MAb KI. The protein(s) expressed in E. coli were purified and used to make rabbit or mouse antisera. These antisera reacted strongly with a soluble cytosolic protein in OVCAR-3 cells, but not with the membrane-bound antigen. Soluble cytosolic proteins of a similar size, recognized with MAb KI, were found in OVCAR-3 and N87 (gastric cancer) cells but not in 10 other cancer cell lines. These data indicate that the cloned cDNA encodes a cytosolic protein that reacted with MAb KI. This soluble protein is expressed only in cells containing the CAKI surface glycoprotein, suggesting that the 2 proteins could be structurally related.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8150545     DOI: 10.1002/ijc.2910570117

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.

Authors:  Hector Alvarez; Pamela Leal Rojas; Ken-Tye Yong; Hong Ding; Gaixia Xu; Paras N Prasad; Jean Wang; Marcia Canto; James R Eshleman; Elizabeth A Montgomery; Anirban Maitra
Journal:  Nanomedicine       Date:  2008-08-08       Impact factor: 5.307

2.  Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.

Authors:  Junko Yokokawa; Claudia Palena; Philip Arlen; Raffit Hassan; Mitchell Ho; Ira Pastan; Jeffrey Schlom; Kwong Y Tsang
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

3.  fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.

Authors:  Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Expert Opin Med Diagn       Date:  2011-05-01

Review 4.  Serum mesothelin and other biomarkers: what have we learned in the last decade?

Authors:  Alfonso Cristaudo; Alessandra Bonotti; Giovanni Guglielmi; Poupak Fallahi; Rudy Foddis
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

Authors:  M W McIntosh; C Drescher; B Karlan; N Scholler; N Urban; K E Hellstrom; I Hellstrom
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

6.  Aberrant Expression of Calretinin, D2-40 and Mesothelin in Mucinous and Non-Mucinous Colorectal Carcinomas and Relation to Clinicopathological Features and Prognosis.

Authors:  Abd AlRahman Mohammad Foda; Amira Kamal El-Hawary; Hazem Hamed
Journal:  Pathol Oncol Res       Date:  2016-04-09       Impact factor: 3.201

7.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

Authors:  K Chang; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

8.  Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells.

Authors:  Shayna L Showalter; Yu-Hung Huang; Agneszka Witkiewicz; Christina L Costantino; Charles J Yeo; Jordan J Green; Robert Langer; Daniel G Anderson; Janet A Sawicki; Jonathan R Brody
Journal:  Cancer Biol Ther       Date:  2008-10-03       Impact factor: 4.742

9.  Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?

Authors:  Dimitra Sasaroli; George Coukos; Nathalie Scholler
Journal:  Biomark Med       Date:  2009-06-01       Impact factor: 2.851

Review 10.  Current developments in adenovirus-based cancer gene therapy.

Authors:  Daniel T Rein; M Breidenbach; David T Curiel
Journal:  Future Oncol       Date:  2006-02       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.